Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Liposomal Irinotecan in Combination With Oxaliplatin and Bevacizumab Versus Liposomal Irinotecan in Combination With 5-FU/LV for the Second-line Treatment of Advanced Pancreatic Cancer

NCT06782685 is registered in ClinicalTrials.gov with Dai, Guanghai as lead sponsor.

NCT NCT06782685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06782685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Liposomal Irinotecan in Combination With Oxaliplatin and Bevacizumab Versus Liposomal Irinotecan in Combination With 5-FU/LV for the Second-line Treatment of Advanced Pancreatic Cancer
Lead sponsor
Dai, Guanghai
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 23, 2024
Completion date
March 31, 2027
Enrollment
138 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic cancer (part 1)